vasopharm Appoints Chief Medical Officer

Irina Antonijevic, MD PhD joins vasopharm management team

Würzburg, Germany – November 8, 2016 –  vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer.

In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.

Full press release here